Liposomal Ivermectin
Experimental evidence, formulation notes, recipe math, and safety cautions for liposomal ivermectin
This page covers the experimental liposomal ivermectin material in this section.
It is one of the highest-risk topics here.
That is why the emphasis on safety is stronger than usual.
No formal approval exists for routine human use of liposomal ivermectin. Oral liposomal ivermectin remains experimental. Extreme caution is warranted, especially with high dosing, CNS risk, or Fenbendazole co-use.
What the preclinical studies suggest
The early literature points in one direction:
higher intracellular uptake
improved delivery performance in preclinical systems
lower apparent cytotoxicity than free ivermectin in some models
Key studies cited
1. Enhanced intracellular uptake and reduced toxicity
Enhancing Intracellular Uptake of Ivermectin through Liposomal Encapsulation: An In Vitro Study
Reported uptake range: 13–60% for liposomal ivermectin versus about 2% for free ivermectin in the cited system
2. Antiviral activity against the dengue virus
Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin
3. In vitro antiviral potency
Development and in vitro antiviral activity of ivermectin liposomes as a potential drug carrier system https://www.unboundmedicine.com/medline/citation/38702288/
Practical interpretation
These papers support a cautious conclusion.
Liposomal ivermectin may:
increase delivery into cells
improve pharmacokinetic behaviour
improve tissue targeting
reduce free-drug cytotoxicity in some systems
That still does not make DIY use simple or automatically safe.
Other pages in this section
Practical considerations for liposomal Ivermectin
Solubility and compatibility
Ivermectin is highly hydrophobic.
It is practically insoluble in water.
It is much more compatible with organic solvents such as ethanol or methanol.
That is one reason liposomal encapsulation is being explored.
Why liposomal delivery may be attractive
Liposomal ivermectin may offer:
substantially higher cellular uptake
improved bioavailability
better tissue targeting
protection from enzymatic degradation
reduced cytotoxicity in some preclinical settings
Size and encapsulation questions
80–200 nm liposomes are often described as a common and effective range.
It also notes that some positively charged liposomes can be smaller.
Encapsulation efficiency is often reported above 80%. Optimised research methods sometimes report 95–100%.
Storage and stability
Cool storage is preferred.
Refrigeration is preferred.
It also notes that some members are using amber syringes with caps for pre-measured daily doses.
Those syringes may help with:
light protection
faster dosing
labelling
safer fridge storage away from children
Regulatory note
Ivermectin is prescription-only in Australia and many other countries for oral use.
Liposomal ivermectin is not formally approved by the TGA for human use.
This remains an experimental area and is subject to local regulation.
Liposomal Ivermectin recipe example
One worked example uses:
1 gram ivermectin
7 mL of 96-proof alcohol
10 mL of MCS Liposence
That gives a total volume of:
17 mL
Concentration math
total ivermectin: 1,000 mg
total volume: 17 mL
concentration:
1,000 mg ÷ 17 mL ≈ 58.82 mg/mL
Dose per 0.5 mL
58.82 mg/mL × 0.5 mL ≈ 29.41 mg
That rounds to:
about 30 mg ivermectin per 0.5 mL
Starting-dose caution
Extra caution makes sense the first time.
One conservative approach is to halve the usual dose when switching to a liposomal formulation.
The example given is:
if someone usually takes 30 mg oral powder
a safer first liposomal starting point may be 0.25 mL rather than 0.5 mL
That is still experimental guidance only.
It is not a validated dosing protocol.
Handling tips
swirl or shake gently before each dose
use an accurate syringe for small volumes
store smaller batches in the fridge
label bottles or syringes clearly
Important safety considerations
Timing matters.
What is already in your blood matters.
Fenbendazole is used as the example.
The concern is that fenbendazole is:
slower to absorb than ivermectin
able to peak many hours later
potentially still present when a later liposomal dose is introduced
That matters because liposomes may make cell entry easier not only for the intended payload, but sometimes also for fat-soluble compounds still circulating nearby.
Fenbendazole timing concern
The practical concern is:
Fenbendazole may peak anywhere from 3–30 hours later
average estimates are roughly 6–12 hours
half-life ranges discussed in the literature are about 10–30 hours across studies and species
That is one reason wider spacing is sensible.
Member report kept clearly separate
Member report
A community report describes taking 200 mg liposomal Mebendazole made with MCS Liposense about 2 hours after 30 mg powdered ivermectin.
The reported effects were stronger and more difficult to tolerate than with previous non-liposomal use within a similar time window.
This is a personal report.
It is not trial evidence.
It still matters because it shows that liposomal delivery may radically change tolerability.
Bottom line
Liposomal ivermectin is biologically interesting and of high practical risk.
The two most important takeaways are:
go gradually
go safely
That means:
lower starting doses
wider spacing
careful monitoring
much more respect for CNS exposure questions
→ Back to How to Use Empty Liposomes
→ Previous: DIY Liposomal Melatonin
→ Next: Nebulising Liposomal Formulations
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.